Skip to main content
S

SCL Science Inc. — Investor Relations & Filings

Ticker · 246960 ISIN · KR7246960009 KO Professional, scientific and technical activities
Open in API
Filings indexed 309 across all filing types
Latest filing 2022-03-31 Declaration of Voting R…
Country KR South Korea
Listing KO 246960

About SCL Science Inc.

https://sclscience.com/en

SCL Science Inc., formerly InnoTherapy Inc., is a healthcare company focused on digital innovation and advanced medical technologies. The company develops and commercializes medical hemostatic agents based on its proprietary biomimetic technology, including the Bio-inspired Medical Materials (BiMM) product line. Leveraging 40 years of expertise in medical science, SCL Science is also dedicated to building a digital healthcare ecosystem using artificial intelligence and high-quality medical data. Its services extend to clinical trial analysis, bio-logistics, and an expanding drug discovery platform focused on AI-driven cancer vaccine development. The company serves hospitals, research laboratories, and other medical institutions.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, director and auditor appointments, and remuneration limits. This document is the official record of the voting outcomes from the Annual General Meeting, which aligns perfectly with the definition for Declaration of Voting Results & Voting Rights Announcements.
2022-03-31 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 1% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the granting of stock options (주식매수선택권 부여). It details the number of shares, exercise price, grant date, and the list of recipients (directors and employees). This type of disclosure regarding capital structure changes and equity-based compensation for executives/employees falls under the category of 'Share Issue/Capital Change' (SHA) as it relates to the issuance of new shares upon exercise of options.
2022-03-31 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details changes in share ownership by major shareholders and special related parties, including the reason for the change (stock option grants). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-03-31 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) submitted to the Korea Exchange (KRX). It provides the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, equity, profit/loss), and details regarding the auditor (Anjin Accounting Corp). While it contains financial data, it is a standard regulatory disclosure announcement regarding the receipt and submission of the audit report, rather than the full annual report (10-K) itself. Under the 'Menu vs Meal' rule, this is a formal regulatory filing announcing the audit results. FY 2021
2022-03-23 Korean
사업보고서 (2021.12)
Annual Report Classification · 1% confidence The document is titled '사업보고서' (Business Report) for the 12th fiscal year (2021), which is the standard terminology for an Annual Report in South Korea. It contains comprehensive sections including company overview, business description, financial statements, management discussion and analysis, and auditor's opinion. It is a full-length regulatory filing submitted to the Financial Supervisory Service and Korea Exchange, fitting the definition of a 10-K (Annual Report). FY 2021
2022-03-23 Korean
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company could not avoid the designated 'concentrated' dates for their AGM due to audit and financial reporting schedules. Since this is a specific regulatory disclosure regarding meeting logistics and compliance with exchange guidelines, and does not fit into the specific categories of AGM materials, proxy statements, or dividend announcements, it is best classified as a general regulatory filing.
2022-03-16 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.